The CEO's open-market purchase at the current market price is a strong insider signal. Monitor for upcoming Phase 2a data readouts for foralumab in na-SPMS, which could be the next major catalyst.
Price Chart
Executive Summary
CEO Ivor Elrifi purchased 667,000 TLSA common shares at $1.00 per share on the open market, increasing his total holding to 4,472,261 shares. This insider open-market buy signals management's confidence in the company's pipeline, particularly intranasal foralumab for non-active secondary progressive multiple sclerosis. The purchase represents a meaningful personal investment at the current market price.
Key Facts
- CEO Ivor Elrifi purchased 667,000 TLSA common shares on NASDAQ at $1.00 per share.
- CEO's total holding increased to 4,472,261 common shares.
- Purchase announced via press release on August 4, 2026.
- Tiziana is a clinical-stage biotech developing intranasal foralumab, a fully human anti-CD3 mAb, for neuroinflammatory diseases.
- Foralumab is being studied in a Phase 2a trial (NCT06292923) for non-active secondary progressive multiple sclerosis.
- 14 patients in an Expanded Access Program showed improvement or stability within 6 months.
Financial Impact
CEO invested $667,000 at $1.00/share, representing a meaningful insider vote of confidence.
Risk Factors
- Clinical-stage biotech with no approved products; pipeline risk is high.
- Foralumab is still in early-to-mid-stage trials; regulatory and commercial uncertainty remains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-084894 |
| Document: ea030048501ex99-1.htm | 0001213900-26-084894 |
| Document: 0001213900-26-084894-index-headers.html | 0001213900-26-084894 |
| Document: 0001213900-26-084894-index.html | 0001213900-26-084894 |
| Document: 0001213900-26-084894.txt | 0001213900-26-084894 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8800 (−12.87%) |
Oct 16, 2026 10d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8800 (+12.87%) |
Oct 16, 2026 11d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8800 (−16.19%) |
Sep 30, 2026 27d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8800 (−20.72%) |
Sep 28, 2026 29d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8800 (−10.20%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8800 (−2.72%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8800 (−9.28%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8800 (−9.28%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8800 (−23.48%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8800 (−9.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers